FR3035120B1 - Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition - Google Patents

Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition Download PDF

Info

Publication number
FR3035120B1
FR3035120B1 FR1553347A FR1553347A FR3035120B1 FR 3035120 B1 FR3035120 B1 FR 3035120B1 FR 1553347 A FR1553347 A FR 1553347A FR 1553347 A FR1553347 A FR 1553347A FR 3035120 B1 FR3035120 B1 FR 3035120B1
Authority
FR
France
Prior art keywords
composition
plasminogenase
preparation
blood plasma
solid support
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1553347A
Other languages
English (en)
Other versions
FR3035120A1 (fr
Inventor
Gerard Reboul
Carine SAUX
Francoise Ouarne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcadophta
Original Assignee
Arcadophta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcadophta filed Critical Arcadophta
Priority to FR1553347A priority Critical patent/FR3035120B1/fr
Priority to US15/566,642 priority patent/US20180135038A1/en
Priority to PCT/FR2016/050869 priority patent/WO2016166484A1/fr
Priority to JP2018505541A priority patent/JP2018515131A/ja
Priority to EP16729958.5A priority patent/EP3283626A1/fr
Priority to CN201680034582.2A priority patent/CN107787366A/zh
Publication of FR3035120A1 publication Critical patent/FR3035120A1/fr
Application granted granted Critical
Publication of FR3035120B1 publication Critical patent/FR3035120B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C12N11/087—Acrylic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition enzymatique comprenant : au moins une enzyme, dite plasminogénase, de conversion en plasmine de plasminogène d'un milieu plasmatique sanguin comprenant du plasminogène ; - un support solide insoluble en solution aqueuse, ladite plasminogénase étant liée au support solide et restant liée à ce support au contact d'un milieu plasmatique sanguin, caractérisée en ce que le support solide est formé d'un matériau poreux et présente des dimensions adaptées pour pouvoir être retenu sur un filtre présentant un seuil de coupure inférieur ou égal à 0,22 µm. L'invention concerne également un procédé de préparation d'une telle composition enzymatique, son utilisation et un dispositif (20) pour la préparation d'un milieu plasmatique sanguin ex vivo riche en plasmine stérile et exempt de composition enzymatique.
FR1553347A 2015-04-15 2015-04-15 Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition Expired - Fee Related FR3035120B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1553347A FR3035120B1 (fr) 2015-04-15 2015-04-15 Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition
US15/566,642 US20180135038A1 (en) 2015-04-15 2016-04-14 Immobilized plasminogenase composition, preparation process, use and device comprising such a composition
PCT/FR2016/050869 WO2016166484A1 (fr) 2015-04-15 2016-04-14 Composition de plasminogénase immobilisée, procédé de préparation, utilisation et dispositif comprenant une telle composition
JP2018505541A JP2018515131A (ja) 2015-04-15 2016-04-14 固定化プラスミノゲナーゼ組成物、調製方法、使用、及びかかる組成物を含む装置
EP16729958.5A EP3283626A1 (fr) 2015-04-15 2016-04-14 Composition de plasminogénase immobilisée, procédé de préparation, utilisation et dispositif comprenant une telle composition
CN201680034582.2A CN107787366A (zh) 2015-04-15 2016-04-14 固定化的纤溶酶原酶组合物、制备方法、用途和包含此类组合物的装置

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1553347A FR3035120B1 (fr) 2015-04-15 2015-04-15 Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition
FR1553347 2015-04-15

Publications (2)

Publication Number Publication Date
FR3035120A1 FR3035120A1 (fr) 2016-10-21
FR3035120B1 true FR3035120B1 (fr) 2020-02-07

Family

ID=53794324

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1553347A Expired - Fee Related FR3035120B1 (fr) 2015-04-15 2015-04-15 Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition

Country Status (6)

Country Link
US (1) US20180135038A1 (fr)
EP (1) EP3283626A1 (fr)
JP (1) JP2018515131A (fr)
CN (1) CN107787366A (fr)
FR (1) FR3035120B1 (fr)
WO (1) WO2016166484A1 (fr)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54129185A (en) * 1978-03-30 1979-10-06 Unitika Ltd Storing of immobilized enzyme
JPS58124798A (ja) * 1982-01-18 1983-07-25 Dai Ichi Pure Chem Co Ltd α↓２−プラスミンインヒビタ−の精製法
US5714372A (en) * 1985-04-22 1998-02-03 Genentech, Inc. Tissue plasminogen activator variants
JPH02268681A (ja) * 1989-04-07 1990-11-02 Green Cross Corp:The ウロキナーゼ前駆体の安定化方法及び乾燥製剤
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US7939601B1 (en) * 1999-05-26 2011-05-10 Rhodia Inc. Polymers, compositions and methods of use for foams, laundry detergents, shower rinses, and coagulants
CN1188516C (zh) * 1999-09-17 2005-02-09 常荣山 一种重组纳豆激酶的编码核苷酸序列及该酶的制备方法
WO2001070763A1 (fr) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Facteurs de coagulation sanguine modifies et leur procede d'utilisation
RU2213557C2 (ru) * 2001-12-26 2003-10-10 Закрытое акционерное общество "Аксис" Фармацевтическая композиция, обладающая тромболитическими, противовоспалительными и цитопротективными свойствами
US20030148291A1 (en) * 2002-02-05 2003-08-07 Karla Robotti Method of immobilizing biologically active molecules for assay purposes in a microfluidic format
CA2512894A1 (fr) * 2003-01-17 2004-08-05 Ttc Co., Ltd. Reacteur a piege par affinite et procede a une etape servant a purifier un fragment de type angiostatine du plasma humain utilisant ce reacteur
FR2850564B1 (fr) * 2003-02-05 2006-06-02 Arcadophta Dispositif et procede de preparation extemporanee d'une quantite individuelle de fluide sterile
US20050069453A1 (en) * 2003-09-29 2005-03-31 Ren-Yo Forng Methods for sterilizing preparations of urokinase
WO2005072340A2 (fr) * 2004-01-27 2005-08-11 Compugen Ltd. Nouveaux polynucleotides codant pour des polypeptides et leurs procedes d'utilisation
JP2007068497A (ja) * 2005-09-09 2007-03-22 Nihon Pharmaceutical Co Ltd プラスミンの精製法
DE102006008613A1 (de) * 2006-02-24 2007-08-30 Dade Behring Marburg Gmbh Stabilisierte Zubereitungen von Serin-Endopeptidasen, deren Herstellung und Verwendung
WO2008121757A1 (fr) * 2007-03-30 2008-10-09 Centocor Inc Clones à expression élevée de cellules mammifères avec une protéine fluorescente a ou g
US20100272740A1 (en) * 2007-10-17 2010-10-28 Alexey Vertegel Micro- and nanoscale devices for delivery of active fibronolytic agents
EP2220221B1 (fr) * 2007-11-29 2014-12-31 Grifols Therapeutics Inc. Plasmine modifiée de manière recombinante
CN201351160Y (zh) * 2008-05-20 2009-11-25 博傲西腾医疗科技(上海)有限公司 自体血纤维蛋白溶解酶原的提取装置
JP2011522538A (ja) * 2008-06-04 2011-08-04 タレクリス・バイオセラピユーテイクス・インコーポレーテツド プラスミン製造のための組成物、方法およびキット
US20110020370A1 (en) * 2008-12-11 2011-01-27 Elias Georges Slc7a5 directed diagnostics and therapeutics for neoplastic disease
FR2941371B1 (fr) * 2009-01-28 2011-01-21 Alaxia Dispositif de preparation extemporanee de preparations medicamenteuses
WO2010125148A2 (fr) 2009-04-30 2010-11-04 Catherine Blondel Méthodes de traitement de pathologies oculaires

Also Published As

Publication number Publication date
WO2016166484A1 (fr) 2016-10-20
FR3035120A1 (fr) 2016-10-21
EP3283626A1 (fr) 2018-02-21
CN107787366A (zh) 2018-03-09
US20180135038A1 (en) 2018-05-17
JP2018515131A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
AR060894A1 (es) Aparato basado en membrana y metodo asociado
EA201300582A1 (ru) Инъекционное устройство, способ введения текучей среды в инъекционное устройство и комплект для инъекций
BRPI0511686A (pt) dispositivo e método de ensaio de fluxo controlado
WO2006088576A3 (fr) Formulations de polypeptides et leurs procedes de fabrication, d'utilisation et de caracterisation
MX2008007716A (es) Metodo para eliminar extra corporalmente de la sangre un microbio patogeno, una celula inflamatoria o una proteina inflamatoria.
CL2011002274A1 (es) Metodo para detectar la actividad endopeptidasa redirigida que comprende tratar una linea celular establecida con una muestra que comprende la endopeptidasa redirigida, aislar de la celula tratada un componente escision snap25, poner en contacto con un anticuerpo; y anticuerpo utilizado en el método.
CL2012001103A1 (es) Método para reducir el nivel del polipéptido tau desacetilado en una célula, que comprende poner en contacto la célula con un agente que incrementa la actividad de un polipéptido que desacetila tau y/o un agente que disminuye la actividad de un polipéptido que acetila tau; y usos terapéuticos para tratar una tauopatía.
BR122018070775B1 (pt) composição, e material estrutural, elétrico, químico, ou uma combinação dos mesmos
WO2012061227A3 (fr) Indicateur de stérilisation biologique
MX2013011041A (es) Capa de difusion mejorada para sensor enzimatico in vivo.
WO2011140073A3 (fr) Raccord réglable, écoulement amélioré de fluide et risque réduit de coagulation
EP2049652A4 (fr) Revêtements pour capillaires capables de capturer des analytes
WO2007111681A3 (fr) Dispositif et procédé de détection d'agent biologique à base de cristaux liquides
DE602006021340D1 (de) Nukleinsäuredetektion mit poröser polymerelektrode
BRPI0417417A (pt) sistema de coleta de amostra de inibidor de fosfatase
WO2007136640A3 (fr) Procédé de préparation de 2-(2,6-dioxopipéridin-3-yl)isoindole-1,3-dione substitué
CL2009001754A1 (es) Metodo para tratar bananas que comprende poner en contacto dichas bananas con una composicion liquida que comprende un complejo de agente de encapsulacion molecular de ciclopropeno donde la duracion de dicho contacto es de 1 segundo a 4 minutos y se realiza 20 semanas o menos despues de la cosecha.
AR069859A1 (es) Tratamiento de biocombustibles
MA35212B1 (fr) Essai de la lysyl oxydase de type 2 et ses procédés d'utilisation
WO2008107724A3 (fr) Stabilisation de marqueurs biologiques cellulaires
MA37744B1 (fr) Dispositif de diagnostic in vitro et utilisations
PE20190517A1 (es) Preparacion farmaceutica antienvejecimiento
JP2009204612A5 (fr)
FR3035120B1 (fr) Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition
EA200800722A1 (ru) Средство, активирующее стволовые клетки и/или клетки-предшественники

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20161021

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20211205